Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study

MLA

Lianxi Song, et al. “Clinical Activity of Pembrolizumab with or without Chemotherapy in Advanced Pulmonary Large-Cell and Large-Cell Neuroendocrine Carcinomas: A Multicenter Retrospective Cohort Study.” BMC Cancer, vol. 23, no. 1, May 2023, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s12885-023-10952-w.

APA

Lianxi Song, Fei Zhou, Tian Xu, Liang Zeng, Qing Xia, Zhan Wang, Li Deng, Yizhi Li, Haoyue Qin, Huan Yan, Zhe Huang, Jinye Mi, Qinqin Xu, Nong Yang, Caicun Zhou, & Yongchang Zhang. (2023). Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study. BMC Cancer, 23(1), 1–10. https://doi.org/10.1186/s12885-023-10952-w

Chicago

Lianxi Song, Fei Zhou, Tian Xu, Liang Zeng, Qing Xia, Zhan Wang, Li Deng, et al. 2023. “Clinical Activity of Pembrolizumab with or without Chemotherapy in Advanced Pulmonary Large-Cell and Large-Cell Neuroendocrine Carcinomas: A Multicenter Retrospective Cohort Study.” BMC Cancer 23 (1): 1–10. doi:10.1186/s12885-023-10952-w.